SCHEMBL4773065

SCHEMBL4773065

O=C(CCc1c[nH]cn1)Nc1cc(-c2cccnc2)nc(-c2ccccn2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 10/20 0.43
ADORA2A P29274 9/20 0.43
ADORA3 P0DMS8 5/20 0.43
CYP2A6 P11509 1/20 0.40
ADORA2B P29275 1/20 0.40
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CDC7 O00311 1/20 0.38
DAPK3 O43293 1/20 0.38
ROCK2 O75116 1/20 0.38
MAP4K4 O95819 1/20 0.38
PRKACA P17612 1/20 0.38
FLT1 P17948 1/20 0.38
CDK2 P24941 1/20 0.38
CDK8 P49336 1/20 0.38
CLK2 P49760 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4766014 0.88 ADORA1 (0.47) ADORA1ADORA2AADORA3CYP2A6ADORA2B
SCHEMBL4773528 0.85 PTGDR (0.43) CYP2A6NPC1TP53PKMTSHR
SCHEMBL4771758 0.82 ADORA1 (0.43) ADORA1ADORA2AADORA3CYP2A6ADORA2B
SCHEMBL4768684 0.81 ADORA2A (0.43) ADORA1ADORA2AADORA3CYP2A6ADORA2B
SCHEMBL4769102 0.81 KMT2A (0.55) ADORA1ADORA2AADORA3NPC1RAB9A
SCHEMBL4765953 0.80 LMNA (0.52) NPC1TP53PKMTSHRRAB9A
SCHEMBL4770635 0.80 CYP1A2 (0.52) ADORA1ADORA2AADORA3TSHRSMN1; SMN2
SCHEMBL4773165 0.79 CYP2A6 (0.39) CYP2A6NPC1TP53PKMTSHR
SCHEMBL4773182 0.79 CYP2A6 (0.39) CYP2A6NPC1TP53PKMTSHR
SCHEMBL4768829 0.78 KDM4E (0.44) ADORA1ADORA2AADORA3CYP2A6ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed